Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ten years experience with Ewing's sarcoma

M Gasparini, S Barni, A Lattuada

    Tumori
    |January 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Perioperative evaluation of primary hemostasis in patients undergoing mitral valve repair.

    HSR proceedings in intensive care & cardiovascular anesthesia·2013
    Same author

    Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors.

    Oncogene·2008
    Same author

    Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours.

    European journal of cancer (Oxford, England : 1990)·2007
    Same author

    Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.

    British journal of cancer·2005
    Same author

    Changes in health and disease of the metalloprotease that cleaves von Willebrand factor.

    Blood·2001
    Same author

    Undifferentiated nasopharyngeal carcinoma in children and adolescents: comparison between staging systems.

    Annals of oncology : official journal of the European Society for Medical Oncology·2001
    Same journal

    End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

    Tumori·2026
    Same journal

    Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

    Tumori·2026
    Same journal

    Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

    Tumori·2026
    Same journal

    Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

    Tumori·2026
    Same journal

    Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

    Tumori·2026
    Same journal

    Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

    Tumori·2026
    See all related articles

    Chemotherapy significantly improved disease-free survival for Ewing sarcoma patients. Combining treatments like Adriamycin (ADM) with radiotherapy or surgery extended survival from 5 to over 24 months.

    Area of Science:

    • Pediatric Oncology
    • Medical Oncology
    • Skeletal Oncology

    Background:

    • Ewing sarcoma is a rare bone cancer primarily affecting children and young adults.
    • Treatment outcomes for Ewing sarcoma have historically been limited, particularly for advanced disease.

    Purpose of the Study:

    • To evaluate the impact of combined modality treatment on disease-free survival in localized Ewing sarcoma.
    • To assess the efficacy of single-agent and combination chemotherapy regimens in advanced Ewing sarcoma.

    Main Methods:

    • Retrospective analysis of 57 consecutive Ewing sarcoma patients treated between 1965 and 1976.
    • Comparison of outcomes between patients receiving local therapy versus combined modality treatment (radiotherapy/surgery plus chemotherapy).
    • Evaluation of response rates for single-agent Adriamycin and a combination regimen (ADM, VCR, CTX, CCNU) in advanced disease.

    Related Experiment Videos

    Main Results:

    • Patients with localized tumors treated with local therapy before 1971 had a median disease-free survival of 5 months.
    • After 1971, combined modality treatment (local therapy + multi-drug chemotherapy) improved projected median disease-free survival to over 24 months.
    • Single-agent Adriamycin achieved a 73% response rate in advanced disease, comparable to a new combination regimen (75%), which is expected to prolong response duration.

    Conclusions:

    • Combined modality treatment significantly enhances disease-free survival for localized Ewing sarcoma.
    • Adriamycin-based chemotherapy regimens demonstrate high response rates in advanced Ewing sarcoma.
    • Multi-drug chemotherapy combinations hold promise for prolonged response duration in advanced Ewing sarcoma.